☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
aTyr Pharma
aTyr Pharma, Efzofitimod, Systemic Sclerosis-Associated Interstitial Lung Disease, Clinical Trial, P-II Study
March 2, 2023
aTyr Pharma Reports the First Patient Dosing in the P-III (EFZO-FIT) Study of Efzofitimod for the Treatment of Pulmonary Sarcoidos...
September 28, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.